Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 3
2016 2
2017 2
2020 2
2021 6
2022 4
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease.
McKeon A, Lesnick C, Vorasoot N, Buckley MW, Dasari S, Flanagan EP, Gilligan M, Lafrance-Corey R, Miske R, Pittock SJ, Scharf M, Yang B, Zekeridou A, Dubey D, Mills J. McKeon A, et al. Among authors: lesnick c. Neurol Neuroimmunol Neuroinflamm. 2023 Aug 7;10(5):e200145. doi: 10.1212/NXI.0000000000200145. Print 2023 Sep. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37550073 Free PMC article.
Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis.
Boddicker NJ, Achenbach SJ, Parikh SA, Kleinstern G, Braggio E, Norman AD, Rabe KG, Vachon CM, Lesnick CE, Call TG, Olson JE, Cerhan JR, Kay NE, Hanson CA, Shanafelt TD, Slager SL. Boddicker NJ, et al. Among authors: lesnick ce. Leukemia. 2022 May;36(5):1404-1407. doi: 10.1038/s41375-022-01514-3. Epub 2022 Feb 15. Leukemia. 2022. PMID: 35169244 Free PMC article. No abstract available.
Progression and survival of MBL: a screening study of 10 139 individuals.
Slager SL, Parikh SA, Achenbach SJ, Norman AD, Rabe KG, Boddicker NJ, Olson JE, Kleinstern G, Lesnick CE, Call TG, Cerhan JR, Vachon CM, Kay NE, Braggio E, Hanson CA, Shanafelt TD. Slager SL, et al. Among authors: lesnick ce. Blood. 2022 Oct 13;140(15):1702-1709. doi: 10.1182/blood.2022016279. Blood. 2022. PMID: 35969843 Free PMC article.
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
Purroy N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, Zhang W, Rassenti LZ, Kipps TJ, Slager SL, Kay NE, Lesnick C, Shanafelt TD, Ghia P, Scarfò L, Livak KJ, Kharchenko PV, Neuberg DS, Olsen LR, Fan J, Gohil SH, Wu CJ. Purroy N, et al. Among authors: lesnick c. Blood. 2022 Apr 7;139(14):2252-2256. doi: 10.1182/blood.2021013926. Blood. 2022. PMID: 35020831 Free PMC article. No abstract available.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. Wang XV, et al. Among authors: lesnick ce. Blood. 2021 Dec 30;138(26):2810-2827. doi: 10.1182/blood.2020010146. Blood. 2021. PMID: 34407545 Free PMC article. Clinical Trial.
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy.
Kretzmer H, Biran A, Purroy N, Lemvigh CK, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes SM, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. Kretzmer H, et al. Among authors: lesnick c. Blood Cancer Discov. 2021 Jan;2(1):54-69. doi: 10.1158/2643-3230.BCD-19-0058. Epub 2020 Dec 3. Blood Cancer Discov. 2021. PMID: 33604581 Free PMC article.
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL).
Shanafelt TD, Kay NE, Parikh SA, Achenbach SJ, Lesnick CE, Hanson CA, Kleinstern G, Olson JE, Norman AD, Rabe KG, Schwager SM, Call TG, Slager SL. Shanafelt TD, et al. Among authors: lesnick ce. Leukemia. 2021 Jan;35(1):239-244. doi: 10.1038/s41375-020-0799-8. Epub 2020 Mar 18. Leukemia. 2021. PMID: 32203143 Free PMC article. No abstract available.
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.
Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, Norman AD, Rabe KG, Boddicker NJ, Vachon CM, Lesnick CE, Call TG, Brander DM, Rassenti LZ, Kipps TJ, Olson JE, Cerhan JR, Kay NE, Furman RR, Hanson CA, Shanafelt TD, Slager SL. Kleinstern G, et al. Among authors: lesnick ce. Leukemia. 2022 Jan;36(1):119-125. doi: 10.1038/s41375-021-01344-9. Epub 2021 Jul 20. Leukemia. 2022. PMID: 34285341 Free PMC article.
SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells.
Tsukamoto S, Kumazoe M, Huang Y, Lesnick C, Kay NE, Shanafelt TD, Tachibana H. Tsukamoto S, et al. Among authors: lesnick c. Br J Haematol. 2017 Jul;178(1):155-158. doi: 10.1111/bjh.14119. Epub 2016 May 25. Br J Haematol. 2017. PMID: 27220679 Free article. No abstract available.
20 results